Management
Team
Katrien Reynders-Frederix
Chief Executive Officer
Chief Executive Officer
Katrien Reynders-Frederix joined Pan Cancer T since the foundation in September 2020 as Chief Executive Officer.
Mrs. Reynders brings 16 years of international experience in the life science industry, including Biotech. She started her career as a research coordinator and evolved into leadership roles. She led teams and global drug development programs in various indications, notably in the IO field, and at different stages from clinical candidate up to market access. In a previous role, she was program director at Celyad, where she oversaw the program strategy and development of the autologous CAR-T lead asset CYAD-01. Prior to joining Pan Cancer T, she supported research groups at the KU Leuven with Business Development.
Mrs. Reynders holds a Master of Biomedical Sciences at the KU Leuven Belgium, a postgraduate in Business Administration from KU Leuven Belgium and is certified in project management and change management.
Mrs. Reynders brings 16 years of international experience in the life science industry, including Biotech. She started her career as a research coordinator and evolved into leadership roles. She led teams and global drug development programs in various indications, notably in the IO field, and at different stages from clinical candidate up to market access. In a previous role, she was program director at Celyad, where she oversaw the program strategy and development of the autologous CAR-T lead asset CYAD-01. Prior to joining Pan Cancer T, she supported research groups at the KU Leuven with Business Development.
Mrs. Reynders holds a Master of Biomedical Sciences at the KU Leuven Belgium, a postgraduate in Business Administration from KU Leuven Belgium and is certified in project management and change management.
Dr. Rachel Abbott
Chief Scientific Officer
Chief Scientific Officer
Rachel Abbott joined Pan Cancer T in January 2023 as Chief Scientific Officer, bringing a wealth of scientific and industrial expertise in TCR-T cell therapies.
She started her biotech career as a scientist at Adaptimmune and grew into managerial roles where she oversaw the discovery of novel TCRs through T cell cloning, pipeline testing of affinity-enhanced TCRs, and manufacturing large-scale T cells for use in preclinical packages. Rachel led the pipeline project for the development of a T cell therapy directed to PRAME and managed pre-IND safety and efficacy data packages for two next-generation NY-ESO targeting T cell products, all in partnership with GSK. Prior to joining Pan Cancer T, Rachel served as Senior Director, Head of TCR Pipeline and Dark Antigen Research at Enara Bio. In this role, she was responsible for strategic frameworks within research, focusing on the discovery and validation of dark antigens and the identification of dark antigen-specific TCRs.
Rachel holds a DPhil and an MBiochem in Molecular and Cellular Biochemistry, both from the University of Oxford. She was a Research Fellow at the University of Birmingham for seven years.
She started her biotech career as a scientist at Adaptimmune and grew into managerial roles where she oversaw the discovery of novel TCRs through T cell cloning, pipeline testing of affinity-enhanced TCRs, and manufacturing large-scale T cells for use in preclinical packages. Rachel led the pipeline project for the development of a T cell therapy directed to PRAME and managed pre-IND safety and efficacy data packages for two next-generation NY-ESO targeting T cell products, all in partnership with GSK. Prior to joining Pan Cancer T, Rachel served as Senior Director, Head of TCR Pipeline and Dark Antigen Research at Enara Bio. In this role, she was responsible for strategic frameworks within research, focusing on the discovery and validation of dark antigens and the identification of dark antigen-specific TCRs.
Rachel holds a DPhil and an MBiochem in Molecular and Cellular Biochemistry, both from the University of Oxford. She was a Research Fellow at the University of Birmingham for seven years.
Dr. Tom Holdich
Chief Medical Officer
Chief Medical Officer
Dr Tom Holdich is a physician whose specialty is drug development. He has worked in the Pharmaceutical Industry for over 35 years, 18 years in Big Pharma and the last 17 years in Biotech. He has previously sat on the main Board of an AIM listed UK Biotech company for 6 years as R&D Director. His main area is Clinical Development, from Phase 1 through to Life Cycle Management in numerous therapeutic areas. For the last 10 years his focus has been oncology and especially T-cell therapy. From 2014 he was directly involved in the NY-ESO, MAGE-A10, MAGE-A4 and AFP clinical development programmes at Adaptimmune, running first-time-in-man studies and with a remit for late-stage Clinical Development and Medical Affairs. He has also been involved in TIL therapy and consulted on the development of other TCR T-cell therapies. He holds a degree in medicine from The University of London (1982) and has been a Member of the Faculty of Pharmaceutical Medicine (1991).
Dr. Dora Hammerl
VP R&D
VP R&D
Dr. Dora Hammerl is co-founder and VP Research and Development.
Ms. Hammerl brings 7 years of international experience in Immuno-oncology research. She is a member of the Debets laboratory for 5 years, and coordinates the research into PCT targets and their corresponding TCRs.
She has a background in Molecular Biology (2012, University of Vienna) and received her MSc in Biopharmaceutical Sciences (2015) from Leiden University. She worked for 1,5 year at La Jolla Institute, San Diego, CA, in the field of tumor Immunology and joined the Debets Laboratory at Erasmus MC where she obtained her PhD (2020).
Ms. Hammerl brings 7 years of international experience in Immuno-oncology research. She is a member of the Debets laboratory for 5 years, and coordinates the research into PCT targets and their corresponding TCRs.
She has a background in Molecular Biology (2012, University of Vienna) and received her MSc in Biopharmaceutical Sciences (2015) from Leiden University. She worked for 1,5 year at La Jolla Institute, San Diego, CA, in the field of tumor Immunology and joined the Debets Laboratory at Erasmus MC where she obtained her PhD (2020).
Reinout Hesselink
VP Process Development
VP Process Development
Reinout is a seasoned professional in cell and gene therapies manufacturing with over 17 years of experience in CMC, regulatory, and quality assurance.
He has developed cell and gene therapies and production processes from early clinical development to commercial products. He has helped write and file IMPDs, INDs, and market applications. Besides his proven track record as a CMC/ Regulatory and Quality manager, Reinout was general manager. In leading companies such as BioNTech, PhamaCell, and CiMaas.
He has developed cell and gene therapies and production processes from early clinical development to commercial products. He has helped write and file IMPDs, INDs, and market applications. Besides his proven track record as a CMC/ Regulatory and Quality manager, Reinout was general manager. In leading companies such as BioNTech, PhamaCell, and CiMaas.